Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

GLMD Stock  USD 2.68  0.02  0.74%   
About 62% of Galmed Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Galmed Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Galmed Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Galmed Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
Akebia Therapeutics, Inc. , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a Fireside Discussion at the 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3rd at 1030 AM EST.

Read at finance.yahoo.com
Yahoo News
  

Galmed Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Galmed Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Galmed Pharmaceuticals Fundamental Analysis

We analyze Galmed Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Galmed Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Galmed Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Debt

Total Debt Comparative Analysis

Galmed Pharmaceuticals is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Galmed Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Galmed Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Galmed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Galmed Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Galmed Pharmaceuticals Related Equities

APTOAptose Biosciences   5.56   
0%
100.0%
ADAPAdaptimmune Therapeutics   3.39   
0%
60.0%
AFMDAffimed NV   2.94   
0%
52.0%
ACHLAchilles Therapeutics   2.21   
0%
39.0%
FBIOPFortress Biotech   1.52   
0%
27.0%
ABEOAbeona Therapeutics   0.34   
0%
6.0%
AKBAAkebia Ther   0.46   
8.0%
0%
LPTXLeap Therapeutics   1.96   
35.0%
0%
FBIOFortress Biotech   2.14   
38.0%
0%
MBIOMustang Bio   2.99   
53.0%
0%
PDSBPDS Biotechnology   3.13   
56.0%
0%
KODKodiak Sciences   3.25   
58.0%
0%
MREOMereo BioPharma   3.43   
61.0%
0%
ADVMAdverum Biotechnologies   4.42   
79.0%
0%

Complementary Tools for Galmed Stock analysis

When running Galmed Pharmaceuticals' price analysis, check to measure Galmed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galmed Pharmaceuticals is operating at the current time. Most of Galmed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Galmed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galmed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Galmed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
CEOs Directory
Screen CEOs from public companies around the world
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets